A venture backed medical device company, is investigating minimally invasive technology intended to transform the treatment of mitral regurgitation. The company has an exclusive worldwide license to the technology and is currently working on additional minimally invasive technologies for the treatment of structural heart disease.
NeoChord Crosses 150th Patient Milestone!
November 12, 2014
NeoChord Appoints David Chung as President and CEO;
June 24, 2014
- Click for Release -
NeoChord successful live case performed at EACTS.
Nov. 5, 2013
"NeoChord is setting a new standard for minimally invasive mitral valve repair, and at our institution has become the first-line treatment option for degenerative mitral valve regurgitation."
-Professor Gino Gerosa, University of Padova Medical School, Italy.